Sounder than a lifecycle device: Prosonix takes on Novartis (and the rest)
This article was originally published in Scrip
Oxford, UK-based respiratory drug development company Prosonix (slogan - 'Revolutionising Respiratory Medicine') is squaring up to take on pharma giant Novartis, according to CEO David Hipkiss. "Fundamentally I know we're right, and I know we cannot be argued with, because we have the scientific high ground. It sounds a bit arrogant, but it's true!"
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.